Frequently Asked Questions About CMV Management

In this episode, Atul Humar, MD, FRCP(C); Hannah Imlay, MD, MS; and Raymund Razonable, MD, discuss cytomegalovirus (CMV) management strategies in solid organ transplantation recipients, including:

• Evaluation of current data on CMV prevention in liver transplant recipients
• Practical considerations for switching an institution’s antiviral therapy of choice for primary prophylaxis
• Barrier of resistance to antiviral therapies
• Factors to consider when deciding CMV treatment duration
• Use of lymphocyte count to assess CMV cell–mediated immunity

Program Director:

Atul Humar, MD, FRCP(C)
Professor of Medicine
University of Toronto  
Director, Ajmera Transplant Centre
University Health Network
R. Fraser Elliott Chair in Transplantation
Director University of Toronto Transplant Institute
Toronto, Ontario, Canada

Faculty:

Hannah Imlay, MD, MS
Assistant Professor of Medicine
Department of Internal Medicine, Division of Infectious Diseases
University of Utah  
Salt Lake City, Utah

Raymund Razonable, MD
Professor of Medicine
Program Director, Infectious Diseases Fellowship
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota  

Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Follow along with a downloadable slideset at: 
https://bit.ly/476v2wI

Link to full program: 
https://bit.ly/47lNK2K

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.